{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:02:50Z","timestamp":1740146570477,"version":"3.37.3"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0225061","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T13:30:12Z","timestamp":1573565412000},"page":"e0225061","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world evidence of the effectiveness of ombitasvir-paritaprevir\/r \u00b1 dasabuvir \u00b1 ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain"],"prefix":"10.1371","volume":"14","author":[{"given":"Jos\u00e9","family":"Manuel Sousa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"S\u00e1nchez Antol\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lander","family":"Hijona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Carnicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Salmer\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Mateos-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Jou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjam\u00edn","family":"Polo-Lorduy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Rub\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Escarda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Ald\u00e1miz-Echevarr\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Garc\u00eda-Buey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-6081","authenticated-orcid":true,"given":"Jos\u00e9 A.","family":"Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Hern\u00e1ndez-Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Chimeno-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-5049","authenticated-orcid":true,"given":"Rosa M\u00aa","family":"Morillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Magaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Moreno-Planas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Est\u00e9banez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikel","family":"Rico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Sampedro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-3260","authenticated-orcid":true,"given":"Lu\u00eds","family":"Morano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Zozaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senador","family":"Mor\u00e1n-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Mart\u00edn-Granizo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Von-Wichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcial","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1536-3560","authenticated-orcid":true,"given":"Amanda","family":"Manzanares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"issue":"3","key":"pone.0225061.ref001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCVC","year":"2017","journal-title":"The lancet Gastroenterology & hepatology"},{"key":"pone.0225061.ref002","unstructured":"World Health Organization. Hepatitis C. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 2018. 2018;doi."},{"issue":"1","key":"pone.0225061.ref003","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1016\/S0168-8278(17)30857-7","article-title":"Prevalence of hepatitis C in the spanish population. The prevhep study (ethon cohort)","volume":"66","author":"AC Lavin","year":"2017","journal-title":"Journal of hepatology"},{"issue":"3","key":"pone.0225061.ref004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1157\/13090276","article-title":"Hepatitis C in Spain","volume":"127","author":"M Bruguera","year":"2006","journal-title":"Medicina clinica"},{"issue":"1","key":"pone.0225061.ref005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"JP Messina","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"pone.0225061.ref006","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gastrohep.2017.09.004","article-title":"Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years","volume":"41","author":"D Acero Fernandez","year":"2018","journal-title":"Gastroenterologia y hepatologia"},{"issue":"Suppl 1","key":"pone.0225061.ref007","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jis927","article-title":"An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection","volume":"207","author":"AY Kim","year":"2013","journal-title":"The Journal of infectious diseases"},{"issue":"2","key":"pone.0225061.ref008","doi-asserted-by":"crossref","first-page":"ofw059","DOI":"10.1093\/ofid\/ofw059","article-title":"Human Immunodeficiency Virus\/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics","volume":"3","author":"J Berenguer","year":"2016","journal-title":"Open forum infectious diseases"},{"issue":"2","key":"pone.0225061.ref009","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"SL Chen","year":"2006","journal-title":"International journal of medical sciences"},{"issue":"1","key":"pone.0225061.ref010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","volume":"66","author":"European Association for the Study of the Liver (EASL)","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0225061.ref011","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","journal-title":"Hepatology"},{"issue":"17","key":"pone.0225061.ref012","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"21","key":"pone.0225061.ref013","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"P Ferenci","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"2","key":"pone.0225061.ref014","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jhep.2015.10.005","article-title":"Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir\/paritaprevir\/r and dasabuvir for 12weeks","volume":"64","author":"JJ Feld","year":"2016","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0225061.ref015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/jiw597","article-title":"TURQUOISE-I Part 1b: Ombitasvir\/Paritaprevir\/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir","volume":"215","author":"D Wyles","year":"2017","journal-title":"The Journal of infectious diseases"},{"issue":"3","key":"pone.0225061.ref016","doi-asserted-by":"crossref","first-page":"ofx154","DOI":"10.1093\/ofid\/ofx154","article-title":"Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir +\/- Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2","volume":"4","author":"JK Rockstroh","year":"2017","journal-title":"Open forum infectious diseases"},{"volume-title":"Strategic Plan for Tackling Hepatitis C in the Spanish National Health System","year":"2015","author":"Affairs OotSfHaC","key":"pone.0225061.ref017"},{"key":"pone.0225061.ref018","unstructured":"European Medicines Agency (EMA). EPAR-Product Information Viekirax\u00ae. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/viekirax-epar-product-information_en.pdf. Accessed 2018.2015;doi."},{"key":"pone.0225061.ref019","unstructured":"European Medicines Agency (EMA). EPAR-Product Information Exviera\u00ae. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/exviera-epar-product-information_en.pdf. Accessed 2018. 2015."},{"key":"pone.0225061.ref020","unstructured":"Gu\u00edas AEEH\/SEIMC de manejo de la Hepatitis C. Available at: http:\/\/aeeh.es\/wp-content\/uploads\/2017\/06\/consenso.pdf. Accessed 2018.2017;doi."},{"issue":"6","key":"pone.0225061.ref021","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort","volume":"66","author":"JL Calleja","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0225061.ref022","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000454819","article-title":"Universal Sustained Viral Response to the Combination of Ombitasvir\/Paritaprevir\/Ritonavir and Dasabuvir with\/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4","volume":"45","author":"S Abad","year":"2017","journal-title":"American journal of nephrology"},{"issue":"17","key":"pone.0225061.ref023","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"JJ Feld","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"21","key":"pone.0225061.ref024","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"F Poordad","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"2","key":"pone.0225061.ref025","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"P Andreone","year":"2014","journal-title":"Gastroenterology"},{"issue":"9986","key":"pone.0225061.ref026","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial","volume":"385","author":"C Hezode","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"pone.0225061.ref027","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jvh.12722","article-title":"Real-world effectiveness of ombitasvir\/paritaprevir\/ritonavir+\/-dasabuvir+\/-ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis","volume":"24","author":"H Wedemeyer","year":"2017","journal-title":"Journal of viral hepatitis"},{"issue":"10","key":"pone.0225061.ref028","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/jvh.12708","article-title":"Real-world experience with the all-oral, interferon-free regimen of ombitasvir\/paritaprevir\/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry","volume":"24","author":"TM Welzel","year":"2017","journal-title":"Journal of viral hepatitis"},{"issue":"11","key":"pone.0225061.ref029","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jvh.12945","article-title":"Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir\/paritaprevir\/ritonavir+\/-dasabuvir+\/-ribavirin in the AMBER, real-world experience study","volume":"25","author":"R Flisiak","year":"2018","journal-title":"Journal of viral hepatitis"},{"issue":"9","key":"pone.0225061.ref030","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/QAD.0000000000001465","article-title":"Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection","volume":"31","author":"ML Montes","year":"2017","journal-title":"AIDS (London, England)"},{"issue":"8","key":"pone.0225061.ref031","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"JK Rockstroh","year":"2015","journal-title":"The lancet HIV"},{"key":"pone.0225061.ref032","unstructured":"Fried MD, Vierling AM, Gane E, Nevens F, Strasser S, Weiland O, et al. Safety of ABT-450\/Ritonavir\/Ombitasvir + Dasabuvir with or without Ribavirin in HCV genotype 1-infected patients: Results from phase 2 and 3 trials [abstract 1951]. AASLD 2014 Boston MA USA. 2014;doi."},{"key":"pone.0225061.ref033","unstructured":"Ferenci P, Buggisch P, Norris S, Kleine H, Charafeddine M, Crown E. Safety and effectiveness of ombitasvir\/paritaprevir\/ ritonavir and dasabuvir with ribavirin in HCV genotype 1 and 4-infected patients treated for 12 weeks: real world evidence from a global multicountry observational study. AASDLD. 2017;doi."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0225061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T13:30:31Z","timestamp":1573565431000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0225061"}},"subtitle":[],"editor":[{"given":"Heidar","family":"Sharafi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0225061","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,11,12]]}}}